Category Archives: Cardiovascular

Novo Nordisk ADRs Climb After Study Suggests Its Wegovy Showed Heart Benefits

Key Takeaways Novo Nordisk reported its diabetes and weight-loss drug, Wegovy, helped reduce risks of heart attack, stroke, or death from cardiovascular disease. The drug maker said a Phase 3 trial showed the treatment reduced major adverse cardiovascular events in those with heart conditions and obesity. Novo Nordisk is petitioning U.S. and EU regulators to […]

Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds

Taking semaglutide, the active ingredient in drugs like Wegovy and Ozempic used for weight loss, can help boost heart health in people without diabetes, according to new research. In a study of over 17,000 people, semaglutide, a GLP-1 receptor agonist medication, was found to lower the risk of cardiovascular events like heart attacks and strokes […]

Better heart health may improve cognitive health in kids

Grade school-age children with better cardiovascular health may have better cognitive function, according to new research. Scientists are increasingly looking at the mind-body connection, including how heart health might affect brain function. Past studies of adults have linked poor cardiovascular health to a higher risk of cognitive decline, but there’s been little research on how […]

AHA: PREVENT Risk Calculator Estimates Risk for Cardiovascular Disease

MONDAY, Nov. 13, 2023 (HealthDay News) — The Predicting Risk of Cardiovascular Disease (CVD) Events (PREVENT) risk calculator estimates the risk for CVD, including heart failure, according to a methods paper and accompanying scientific statement published online Nov. 10 in Circulation to coincide with the American Heart Association Scientific Sessions 2023, held from Nov. 11 […]

Interventions that reduce inflammation may reduce incidence of type 2 diabetes, cardiovascular disease

<div data-thumb="https://scx1.b-cdn.net/csz/news/tmb/2023/interventions-that-red.jpg" data-src="https://scx2.b-cdn.net/gfx/news/2023/interventions-that-red.jpg" data-sub-html="WAT IL-1β-secretion induced by the 7-incubation-conditions in all subjects. Credit: Scientific Reports (2023). DOI: 10.1038/s41598-023-45870-1″> WAT IL-1β-secretion induced by the 7-incubation-conditions in all subjects. Credit: Scientific Reports (2023). DOI: 10.1038/s41598-023-45870-1 Canadian scientists have established for the first time a new mechanism and role for LDL in the development of type 2 diabetes, […]

Ozempic, Wegovy Can Reduce Heart Attack Risk by 28%, What to Know

Share on PinterestThe medication semaglutide is being studied as way to help fight heart disease. Antonio Diaz/Getty Images New research presented at the American Heart Association Scientific Sessions indicates that semaglutide has significant effects on heart health. Evidence showed that patients treated with the drug had a reduced risk of heart attack and stroke. Symptoms […]

Elucid collects $80M for AI-powered mapping of blocked arteries

The cardiovascular imaging company Elucid has made it clear they mean to deliver on their promise of artificial intelligence-powered exams to chart the insides of blocked arteries. And now they’ve raised $80 million to do so. Financially speaking, the startup has kept up its momentum since last year’s venture capital fundraising—with a $27 million series […]

Obesity drug Wegovy reduces cardiovascular risks for those at high risk

Enlarge / Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Getty | Michael Siluk The blockbuster diabetes and weight loss drug semaglutide (Wegovy, Ozempic, Rybelsus) reduced the relative risk of heart attack, stroke, or cardiovascular deaths by 20 percent in high-risk patients with cardiovascular disease but not diabetes during a […]

Novel siRNA therapeutic could lower cardiovascular disease risk

A Phase II trial for the small interfering RNA (siRNA) therapeutic lepodisiran is currently underway, assessing its ability to reduce lipoprotein(a) levels. A single dose of lepodisiran, a small interfering RNA (siRNA) therapeutic, produced over 94 percent reductions in blood levels of lipoprotein(a), also known as Lp(a), with the results lasting for nearly a year, […]

Novo Nordisk says Wegovy can help heart disease patients—and not just because it produces weight loss

Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss. Now the Danish company appears on the verge of another breakthrough, showing that the use of its obesity treatment Wegovy can reduce the risk of heart attack in some patients. Perhaps even more importantly, Novo said […]